We are live on
!
Find out more
CS
Candriam SCA Portfolio holdings
AUM
$19.3B
1-Year Est. Return
39.18%
This Fund
S&P 500
This Quarter
Est. Return
-0.77%
1 Year Est. Return
+39.18%
3 Year Est. Return
+109.85%
5 Year Est. Return
+149.31%
10 Year Est. Return
+617.16%
AUM
$7.55B
AUM Growth
-$472M
(-5.9%)
Cap. Flow
-$301M
Cap. Flow
% of AUM
-3.99%
Top 10 Holdings %
Top 10 Hldgs %
20.77%
Holding
863
New
59
Increased
344
Reduced
256
Closed
128
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Nike
NKE
|
+$25.4M |
| 2 |
AbbVie
ABBV
|
+$21.9M |
| 3 |
KYNB
Kyntra Bio
KYNB
|
+$19.2M |
| 4 |
Waste Management
WM
|
+$19M |
| 5 |
Gilead Sciences
GILD
|
+$17.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CELG
Celgene Corp
CELG
|
+$70.2M |
| 2 |
ARRY
Array Biopharma Inc
ARRY
|
+$45.8M |
| 3 |
Biogen
BIIB
|
+$43.3M |
| 4 |
Meta Platforms (Facebook)
META
|
+$24.8M |
| 5 |
Amgen
AMGN
|
+$21.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 31.81% |
| 2 | Technology | 18.27% |
| 3 | Financials | 10.05% |
| 4 | Consumer Discretionary | 9.39% |
| 5 | Communication Services | 7.66% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
LPT
651
DELISTED
Liberty Property Trust
LPT
| $550K | 0.01% |
10,712
+1,321
| +14% | +$68.1K |
|
|
CAJ
652
DELISTED
Canon, Inc.
CAJ
| $546K | 0.01% |
20,454
-53
| -0.3% | -$1.44K |
|
|
VRAY
653
DELISTED
ViewRay, Inc.
VRAY
| $538K | 0.01% |
185,357
+99,000
| +115% | +$587K |
|
654
XPO
XPO
$24.3B
| $534K | 0.01% |
21,576
-2,937
| -12% | -$67.9K |
|
655
Itron
ITRI
$3.7B
| $533K | 0.01% |
7,205
+2,272
| +46% | +$153K |
|
656
Rogers Communications
RCI
$17.8B
| $533K | 0.01% |
10,933
-8,188
| -43% | -$422K |
|
657
ASE Group
ASX
$80.1B
| $519K | 0.01% |
116,425
+980
| +0.8% | +$4.31K |
|
658
Travel + Leisure Co
TNL
$4.66B
| $517K | 0.01% |
11,237
+5,985
| +114% | +$267K |
|
659
Roku
ROKU
$21.2B
| $507K | 0.01% |
+4,985
| New | +$610K |
|
|
RDHL
660
Redhill Biopharma
RDHL
$4.24M
| $502K | 0.01% |
71
| – | – |
|
|
HBI
661
DELISTED
Hanesbrands
HBI
| $500K | 0.01% |
32,640
+7,434
| +29% | +$113K |
|
|
XIFR
662
XPLR Infrastructure LP
XIFR
$1.19B
| $497K | 0.01% |
9,410
+191
| +2% | +$9.6K |
|
663
Voya Financial
VOYA
$9B
| $496K | 0.01% |
9,115
+2,071
| +29% | +$111K |
|
|
MOMO
664
Hello Group
MOMO
$872M
| $465K | 0.01% |
15,000
| – | – |
|
|
AKRO
665
DELISTED
Akero Therapeutics
AKRO
| $455K | 0.01% |
20,000
| – | – |
|
666
United Microelectronic
UMC
$48.1B
| $452K | 0.01% |
216,485
-10,311
| -5% | -$22K |
|
667
Weibo
WB
$1.93B
| $448K | 0.01% |
10,000
+5,000
| +100% | +$212K |
|
|
PHAS
668
DELISTED
PhaseBio Pharmaceuticals, Inc. Common Stock
PHAS
| $440K | 0.01% |
+105,423
| New | +$841K |
|
669
CGI
GIB
$14.5B
| $439K | 0.01% |
5,547
-4,139
| -43% | -$323K |
|
670
Mohawk Industries
MHK
$7.05B
| $426K | 0.01% |
3,436
-4,187
| -55% | -$538K |
|
671
SiriusXM
SIRI
$10.5B
| $423K | 0.01% |
+6,763
| New | +$416K |
|
672
Wayfair
W
$12.4B
| $422K | 0.01% |
3,761
-26
| -0.7% | -$3.33K |
|
|
CBIO
673
Crescent Biopharma
CBIO
$637M
| $418K | 0.01% |
969
| – | – |
|
674
California Water Service
CWT
$3.05B
| $414K | 0.01% |
+7,818
| New | +$419K |
|
675
DaVita
DVA
$15.1B
| $398K | 0.01% |
6,971
+2,496
| +56% | +$145K |
|
Similar funds
PCM
A
MGP
LF
SOMRS
BPA
MIM
Candriam SCA's Q3 2019 Portfolio in Review
As of Q3 2019, Candriam SCA held 863 positions worth $7.55B, down 5.9% from $8.02B the previous quarter. Its ten largest holdings account for 21% of the portfolio.
Candriam SCA withdrew a net $301M in Q3 2019, closing 128 positions and reducing 256 holdings. Its most notable exit was Celgene Corp, an estimated $70.2M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 32% of assets, down from 33% a quarter earlier, followed by Technology and Financials.
Against the trend, Candriam SCA opened a new position in Nike worth $27.8M.
- Candriam SCA's largest Q3 2019 buy was Nike: 295,763 shares worth $27.8M.
- Candriam SCA added most to AbbVie in Q3 2019, an estimated $21.9M increase.
- Candriam SCA's biggest Q3 2019 reduction was Biogen, cutting an estimated $43.3M.
- Candriam SCA fully exited Celgene Corp in Q3 2019, selling an estimated $70.2M.
- Candriam SCA's ten largest holdings make up 21% of its $7.55B portfolio in Q3 2019.
- Candriam SCA opened 59 new positions and closed 128 in Q3 2019.
- Candriam SCA's portfolio value fell 5.9% quarter-over-quarter to $7.55B.
Based on Candriam SCA's 13F filing for Q3 2019, filed 21 Oct 2019.